Prostate Specific Antigen. Current clinical application and future prospects
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F15%3A10294953" target="_blank" >RIV/00216208:11130/15:10294953 - isvavai.cz</a>
Alternative codes found
RIV/00064203:_____/15:10294953
Result on the web
<a href="http://dx.doi.org/10.5507/bp.2014.046" target="_blank" >http://dx.doi.org/10.5507/bp.2014.046</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.5507/bp.2014.046" target="_blank" >10.5507/bp.2014.046</a>
Alternative languages
Result language
angličtina
Original language name
Prostate Specific Antigen. Current clinical application and future prospects
Original language description
Background. Prostate-specific antigen (PSA) is a glycoprotein produced by the prostate gland and its production can be enhanced in benign and malignant diseases. The introduction of PSA testing has greatly increased the detection of prostate cancer. However there is continuing controversy and confusion over the most appropriate application of the PSA test. Methods. PubMed and Web of Science databases were used to search original and review articles on the historical aspects, clinical utilization and possible future directions in PSA. Conclusions. After its discovery, PSA was quickly established as an exquisitely sensitive tumor marker for prostate cancer detection, assessment of treatment responses and follow-up among patients with prostate cancer. Nevertheless, controversy exists about the proper threshold for recommending prostate biopsy. If this limit is lowered to improve the sensitivity even more, patients with low-risk prostate cancer would be subsequently detected. Post-treatmen
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Biomedical Papers
ISSN
1213-8118
e-ISSN
—
Volume of the periodical
159
Issue of the periodical within the volume
1
Country of publishing house
CZ - CZECH REPUBLIC
Number of pages
9
Pages from-to
18-26
UT code for WoS article
000351716500004
EID of the result in the Scopus database
2-s2.0-84924460429